The Latest

  • COUR Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Myasthenia Gravis
  • Skip to primary navigation
  • Skip to main content
  • Skip to footer
COUR Pharmaceuticals Logo

COUR Pharmaceuticals

  • Our Company
    • Leadership
    • Advisors
    • Partners
    • Contact
  • Our Technology
    • Pipeline
    • Autoimmune Diseases
    • Allergies
    • Rare Diseases
    • Gene Therapy
  • Our Clinical Trials
  • Publications & Media
    • Press Releases
    • Publications
  • Careers

In the Press

COUR Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Myasthenia Gravis

October 2022
Read More

COUR Pharmaceuticals Announces $30M Financing Led by Alpha Wave Ventures

September 2022
Read More

COUR NanoParticle (CNP) Technology Induces Antigen Specific Tolerance, Halting the Progression of Type 1 Diabetes in Spontaneous NOD Model

August 2022
Read More

COUR Pharmaceuticals Appoints Brian C. Bock as Chief Financial Officer

March 2022
Read More

Footer

COUR Pharmaceuticals Logo
  • Our Company
  • Our Technology
  • Our Partners
  • Press
  • Careers

©

2023

COUR Pharmaceuticals.
All Rights Reserved.

Privacy Policy • Terms of Use

Back to Top